Serum CXCL10 levels and occurence of thyroid dysfuction in patients treated with iterferon-α theraphy for hepatitis C virus-related hepatitis

European Journal of Endocrinology

Volumn 156, Issue 4, 2007, Pages 409-414

  Rotondi, Mario ^a   Minelli, Roberta ^b   Magri, Flavia ^a   Leporati, Paola ^a   Romagnani, Paola ^c   Baroni, Maria Cristina ^b   Delsignore, Roberto ^b   Serio, Mario ^c   Chiovato, Luca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LEVOTHYROXINE; THIAMAZOLE; THYROID ANTIBODY; THYROID HORMONE;

ARTICLE; AUTOIMMUNE THYROIDITIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GRAVES DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; THYROID DISEASE; THYROID SCINTISCANNING;

ADULT; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; CHEMOKINES, CXC; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; THYROID DISEASES;

EID: 34247617812     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0735     Document Type: Article

References (30)

1. Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T, Unuma T, Okano K, Ikeda Y, Hirano M, Kawase T, Takano S, Matsumoto K, Ohashi Y & Omata M. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999 29 1573-1580.
2. Tran A, Quaranta JF, Benzaken S, Thiers V, Chan HT, Hastier F, Regnier D, Dreyfus G, Pradier C & Sadoul JL. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993 18 253-257.
3. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M & Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon-α-2a. European Journal of Endocrinology 1995 132 587-593.
4. Fernadez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N & Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy. Archives of Internal Medicine 1998 158 1445-1448.
5. Antonelli A, Ferri C, Fallahi P. Ferrari SM, Ghinoi A, Rotondi M & Ferrannini E. Thyroid disorders in hepatitis C virus chronic infection. Thyroid 2006 16 563-572.
6. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY & Chang WY. Virologic factors related to interferon-α-induced thyroid dysfunction in patients with chronic hepatitis C. European Journal of Endocrinology 2000 142 431-437.
7. Lisker-Melman M, Di Bisceglic AM, Usala SJ, Weintraub B, Murray LM & Weissel M. Development of thyroid disease during therapy of chronic viral hepatitis with interferon-α. Gastroenterology 1992 102 2155-2160.
8. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, Chiuchiolo N, Signoriello G, Caporaso N & Lombardi G. Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis. Hormone Research 1995 44 110-114.
9. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, Garcia-Monzon C, Arranz A, Borque MJ & Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clinical Endocrinology 1906 44 635-642.
10. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM & Braverman LE. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. American Journal of Medicine 1996 101 482-487.
11. Zlotnik A & Yoshle O. Chemokines: a new classification system and their role in immunity. Immunity 2000 12 121-127.
12. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R & Strieter RM. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. Journal of Leukocyte Biology 1997 62 554-562.
13. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E & Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 20014 10 50-56.
14. Rotondi M, Lazzeri E, Romagnani P & Serio M. Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field. Journal of Endocrinological Investigation 2003 2 177-180.
15. + lymphocytes. Journal offlinical Endocrinology and Metabolism 2001 86 5008-5016.
16. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A & Serio M. Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-IO/CXCL10 in the serum of subjects with recent onset Graves' disease. American Journal of Pathology 2002 161 195-206.
17. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E & Serio M. High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2004 89 5496-5499.
18. Narumi S, Tominaga Y, Tamaru M, Shimai S, Okamura H, Nishioji K, Itoh Y & Okanoue T. Expression of IFN-inducible protein-10 in chronic hepatitis. Journal of Immunology 1997 158 5536-5544.
19. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM & Kunkel SL. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clinical Science 2003 104 47-63.
20. Itoh Y, Morita A, Nishioji K, Narumi S, Toyama T, Daimon Y, Nakamura H, Kirishima T & Okanoue T. Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. Journal of Viral Hepatitis 2001 8 341-348.
21. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers T, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM & Dustin LB. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005 106 1175-1182.
22. Carella C, Mazziotti G, Amato G, Braverman LE & Roti E. Clinical review 169: interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. Journal of Clinical Endocrinology and Metabolism 2004 89 3656-3661.
23. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, Sorvillo F, Caporaso N & Amato G. Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. Journal of Clinical Endocrinology and Metabolism 2001 86 1925-1929.
24. Oppenheiml Y, Ban Y & Tomer Y. Interferon induced autoimmune thyroid disease (AITD): a model for human autoimmunity. Autoimmunity Review 2004 3 388-393.
25. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG & Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. Journal of Immunology 1999 163 6236-6243.
26. Burman P, Totterman TH, Oberg K & Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. Journal of Clinical Endocrinology and Metabolism 1986 63 1086-1090.
27. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G & Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. New England Journal of Medicine 2006 354 709-718.
28. Rotondi M, Oliviero A, Profice P, Mone CM, Biondi B, Del Buono A, Mazziotti G, Sinisi AM, Bellastella A & Carella C. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. Journal of Endocrinological Investigation 1998 11 748-752.
29. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L & Cosi V. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. Journal of Neuroimmunology 2001 115 192-198.
30. Mazziotti G, Sorvillo F, Piscopo M, Morisco F, Cioffi M, Stornaiuolo G, Gaeta GB, Molinari AM, Lazarus JH, Amato G & Carella C. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. Journal of Clinical Endocrinology and Metabolism 2005 90 4138-4144.